Last reviewed · How we verify
Lispro Mid Mix
Lispro Mid Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics the body's natural insulin secretion pattern by providing both immediate and sustained glucose control.
Lispro Mid Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics the body's natural insulin secretion pattern by providing both immediate and sustained glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Lispro Mid Mix |
|---|---|
| Also known as | Humalog Mix 50/50 |
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin combination therapy |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
The rapid-acting lispro component begins working within 15 minutes to control postprandial (after-meal) blood glucose spikes, while the isophane (NPH) insulin provides a longer duration of action to maintain basal glucose levels between meals and overnight. This combination allows for more physiologic insulin replacement in a single injection, reducing the number of daily injections needed compared to separate rapid and basal insulin regimens.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes (PHASE4)
- Comparison of Insulin Mix25 Versus Mix50 (PHASE4)
- Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast (PHASE4)
- The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (PHASE4)
- Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019) (PHASE4)
- Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lispro Mid Mix CI brief — competitive landscape report
- Lispro Mid Mix updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI